Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + mocetinostat
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Durvalumab + mocetinostat is an investigational combination therapy for cancer, specifically advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC). Durvalumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to counteract tumor immune evasion. Mocetinostat is a selective inhibitor of class I/IV histone deacetylases (HDACs), which can modulate gene expression and potentially enhance the efficacy of immune checkpoint inhibitors like durvalumab by increasing tumor immunogenicity. The combination aims to overcome resistance to checkpoint inhibitors in NSCLC, including in patients previously unresponsive to anti-PD-(L)1 therapies[1][2][4].
- Other names
- durvalumab + mocetinostat
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC2 (Histone deacetylase 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + mocetinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + mocetinostat.